The metabolism and disposition of [ 14 C]apixaban, an orally bioavailable, highly selective,
and direct acting/reversible factor Xa inhibitor, was investigated in 10 healthy male subjects …

Aim Apixaban is an oral, direct, factor‐ X a inhibitor approved for thromboprophylaxis in
patients who have undergone elective hip or knee replacement surgery and for prevention of …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

… All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf
(available on request from the corresponding author) and declare: CE Frost, Y. …

This open‐label study evaluated apixaban pharmacokinetics, pharmacodynamics, and
safety in subjects with mild, moderate, or severe renal impairment and in healthy subjects …

The studies reported here were conducted to investigate the transport characteristics of
apixaban (1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-…

Background and Objectives The effects of age and sex on apixaban pharmacokinetics and
pharmacodynamics were studied. Methods This was an open-label, single-dose, 2 × 2 …

The study described here investigated the impact of intestinal excretion (IE; excretion of drug
directly from circulation to intestinal lumen), enteroenteric recirculation (EER), and renal …

Aims The aims of the present study were to assess the safety, pharmacokinetics (PK) and
pharmacodynamics (PD) of BMS‐962212, a first‐in‐class factor XIa inhibitor, in Japanese and …

This study was conducted to investigate the extent of absorption in different regions of the
gastrointestinal (GI) tract. The relative bioavailability of an apixaban crushed tablet was also …